Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!

The article discusses research on the continued use of sulfonylureas (SU) as first-line add-on to metformin in treating type 2 diabetes. Topics include the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), issues on cardiac safety and hypoglycemia in using SU, its effectivity in lowering glucose levels based on recent meta-analysis studies whether as monotherapy or in combination, and the A Diabetes Outcome Progression Trial (ADOPT) study.